Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection

Eye

Volumn 23, Issue 5, 2009, Pages 1229-

  Scartozzi, R ^a   Chao, J R ^a   Walsh, A C ^a   Eliott, D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; BIOMICROSCOPY; CASE REPORT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER; LASER COAGULATION; LETTER; MALE; OPTICAL COHERENCE TOMOGRAPHY; TREATMENT RESPONSE; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 65949100796     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.162     Document Type: Letter

References (5)

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-1806.
2. Haritoglou C, Kook D, Neubauer A, Wolf A, Pringlinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
3. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867.
4. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1705.
5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182.